Monopar Therapeutics Inc (MNPR)
NASDAQ:MNPR
Want to see MNPR full AI Analyst Report?
Total Valuation
Monopar Therapeutics Inc has a market cap or net worth of $435.10M. The enterprise value is -$51.98B.
Market Cap$435.10M
Enterprise Value-$51.98B
Share Statistics
Monopar Therapeutics Inc has 6,699,062 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding6,699,062
Owned by Insiders17.96%
Owned by Institutions45.93%
Financial Efficiency
Monopar Therapeutics Inc’s return on equity (ROE) is >-0.01 and return on invested capital (ROIC) is -0.01%.
Return on Equity (ROE)>-0.01
Return on Assets (ROA)>-0.01
Return on Invested Capital (ROIC)-0.01%
Return on Capital Employed (ROCE)>-0.01
Revenue Per Employee0.00
Profits Per Employee-979.78K
Employee Count14
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Monopar Therapeutics Inc is ―. Monopar Therapeutics Inc’s PEG ratio is -0.98.
PE Ratio―
PS Ratio0.00
PB Ratio<0.01
Price to Fair Value<0.01
Price to FCF-39.66
Price to Operating Cash Flow-55.37
PEG Ratio-0.98
Income Statement
In the last 12 months, Monopar Therapeutics Inc had revenue of 0.00 and earned -13.72M in profits. Earnings per share was -1.85.
Revenue0.00
Gross Profit0.00
Operating Income-16.70M
Pretax Income-13.72M
Net Income-13.72M
EBITDA-16.70M
Earnings Per Share (EPS)-1.85
Cash Flow
In the last 12 months, operating cash flow was -10.01M and capital expenditures -3.00, giving a free cash flow of -10.01M billion.
Operating Cash Flow-10.01M
Free Cash Flow-10.01M
Free Cash Flow per Share-1.49
Dividends & Yields
Monopar Therapeutics Inc pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.63
52-Week Price Change82.65%
50-Day Moving Average56.95
200-Day Moving Average63.85
Relative Strength Index (RSI)61.18
Average Volume (3m)185.65K
Important Dates
Monopar Therapeutics Inc upcoming earnings date is Aug 6, 2026, Before Open (Confirmed).
Last Earnings DateMay 14, 2026
Next Earnings DateAug 6, 2026
Ex-Dividend Date―
Financial Position
Monopar Therapeutics Inc as a current ratio of 51.35, with Debt / Equity ratio of 0.10%
Current Ratio51.35
Quick Ratio51.35
Debt to Market Cap0.32
Net Debt to EBITDA3.69K
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Monopar Therapeutics Inc has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Monopar Therapeutics Inc EV to EBITDA ratio is 3.66K, with an EV/FCF ratio of 5.02K.
EV to Sales0.00
EV to EBITDA3.66K
EV to Free Cash Flow5.02K
EV to Operating Cash Flow5.02K
Balance Sheet
Monopar Therapeutics Inc has $52.54B in cash and marketable securities with $131.56M in debt, giving a net cash position of $52.41B billion.
Cash & Marketable Securities$52.54B
Total Debt$131.56M
Net Cash$52.41B
Net Cash Per Share$7.82K
Tangible Book Value Per Share$18.60K
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Monopar Therapeutics Inc is $106.28, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$106.28
Price Target Upside89.05% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast―
EPS Growth Forecast40.38%